In HER2-positive gastric cancer, IL2 treatment restored trastuzumab-mediated resistance to ADCC while restoring the expression of the CD16 zeta molecule, which may have implications for the treatment of HER2-positive breast cancer (94). The gene discussed is ERBB2; the disease is breast cancer.